Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc is making significant strides in the radiopharmaceutical sector, particularly with its lead program VMT-α-NET, which is positioned within a potentially multi-billion-dollar market for neuroendocrine tumors (NET) based on positive clinical data. The company’s utilization of the Lead-212 isotope stands out due to its potential for enhanced safety and efficacy, which could provide a considerable competitive edge in the development of targeted cancer therapies. Additionally, the ongoing expansion of manufacturing capabilities and a strategic decentralized network aims to support broad commercial readiness and reliable supply, further reinforcing the positive outlook on the company's growth prospects.

Bears say

Perspective Therapeutics Inc faces substantial risks that contribute to a negative outlook for its stock, primarily linked to the potential for disappointing clinical data from its product candidates, which could significantly undermine market potential and valuation. Additionally, heightened competition and challenges in securing favorable reimbursement could further complicate the company's commercialization efforts, negatively impacting financial performance. Moreover, the decision by Sanofi to deprioritize its radioligand therapy due to safety concerns emphasizes the volatile nature of product development and suggests that without successful partnerships and timely execution, Perspective Therapeutics may struggle to advance its pipeline effectively.

CATX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 9 analysts, CATX has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.